GlassScriptPhysician profile
Joel Wagner
NPI 1356187074
$825.83
in general payments reported to CMS, 2019-2025
10 companies · $560 in 2025
The $560 reported for 2025 was more than what 80% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $266 · 2025: $560.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $826.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $825.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $324.17 | 2024-2025 | Tearcare System, Omni Surgical System |
| Bausch & Lomb Americas INC. | $210.69 | 2024-2025 | Miebo, Xiidra, Vyzulta |
| Abbvie INC. | $72.84 | 2024-2025 | |
| Sun Pharmaceutical Industries INC. | $67.57 | 2025 | |
| Oyster Point Pharma, INC. | $38.09 | 2024-2025 | Tyrvaya, Ryzumvi |
| Tarsus Pharmaceuticals, INC. | $30.90 | 2024 | Xdemvy |
| Harrow Eye, LLC | $25.82 | 2024 | Vevye |
| Alcon Vision LLC | $24.27 | 2025 | Eysuvis |
| Biotissue Holdings INC. | $16.00 | 2025 | |
| Coopervision INC. | $15.48 | 2025 | Biofinity Contact Lens |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joel Wagner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.